Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
November 15, 2013The Journal of RheumatologyOpen Access

Longterm Effect of Delaying Combination Therapy with Tumor Necrosis Factor Inhibitor in Patients with Aggressive Early Rheumatoid Arthritis: 10-year Efficacy and Safety of Adalimumab from the Randomized Controlled PREMIER Trial with Open-label Extension

View Full Paper
Ask AI
Bookmark
Share

Authors

EKEdward KeystoneUniversity of TorontoFBFerdinand C. BreedveldLeiden UniversityDésirée van der HeijdeDésirée van der HeijdeRoche (Switzerland)

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Keystone et al. (2013) studied this question.

synapsesocial.com/papers/6aa754d681e04cd49a18408fhttps://doi.org/10.3899/jrheum.130543
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1\nEULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs.2010 · 1,632 citations
  2. 2American college of rheumatology preliminary definition of improvement in rheumatoid arthritis1995 · 2,851 citations
  3. 3Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti–tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: A randomized, placebo‐controlled, 52‐week trial2004 · 1,174 citations